Jodie has served as president and chief executive officer of Tokai and as a member of the board of directors since March 2013. Prior to her appointment, Jodie served as both the company’s chief operating officer and head of clinical affairs over the seven preceding years. Throughout her tenure at Tokai, Jodie has led the company’s operational management and galeterone prostate cancer development program. Prior to joining Tokai, Jodie was director of clinical operations and medical affairs at Dyax Corporation. During her tenure at Dyax, she built and led the clinical development teams for Kalbitor (hereditary angioedema) and DX-88 (cardiothoracic surgery), and oversaw the Kalbitor clinical trials that ultimately led to its marketing approval. Prior to joining Dyax, she held clinical management positions at both Curis, Inc. and at Diacrin, Inc. Ms. Morrison serves on the board of directors of Keryx Biopharmaceuticals, Inc.
Jodie received a B.A. in neuroscience from Mount Holyoke College, her business training through the Greater Boston Executive Program at MIT Sloan School of Management and her clinical research certification from Boston University School of Medicine.
John is the chief operating officer and chief financial officer of Tokai. Prior to joining Tokai, he founded and served as president of Alliance Life Science Advisors, Inc., a consulting firm focused on assisting life science companies with strategic planning, business development and financing projects. Prior to that, John was executive vice president and chief operating officer of Gloucester Pharmaceuticals, Inc. where he was responsible for the company’s business development, finance, administrative and manufacturing functions. He has also served as global head of oncology licensing at Pharmacia Corporation; executive vice president, business operations and chief financial officer at CytoTherapeutics, Inc.; vice president, business development and treasurer at Phytera, Inc.; vice president, commercial development at Sparta Pharmaceuticals, Inc.; and vice president, business development at U.S. Bioscience, Inc.
John holds a B.S. in biochemistry and an M.S. in chemical engineering from the University of Wisconsin and an M.B.A. from the Wharton School, University of Pennsylvania.